NASDAQ: CMMBChemomab Therapeutics Ltd Stock
$1.35+0.07 (+5.47%)
Updated Apr 30, 2025
CMMB Price
$1.35
Fair Value Price
N/A
Market Cap
$25.46M
52 Week Low
$0.60
52 Week High
$2.55
P/E
-1.73x
P/B
1.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$15M
Beta
0.98
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CMMB Overview
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CMMB's potential to beat the market
- CMMB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CMMB
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important CMMB news, forecast changes, insider trades & much more!
CMMB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CMMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CMMB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CMMB is good value based on its book value relative to its share price (1.88x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
CMMB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CMMB due diligence checks available for Premium users.
Valuation
CMMB fair value
Fair Value of CMMB stock based on Discounted Cash Flow (DCF)
Price
$1.35
Fair Value
$0.35
Overvalued by
281.30%
CMMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CMMB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.73x
Industry
-162.28x
Market
29.18x
CMMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
4.45x
CMMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CMMB's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.0M
Profit Margin
0%
CMMB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$17.0M
Liabilities
$3.4M
Debt to equity
0.25
CMMB's short-term assets ($16.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CMMB's short-term assets ($16.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CMMB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CMMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CMMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CMMB vs Biotech Stocks
Chemomab Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.